Linked Life Data

18317076

Source:http://linkedlifedata.com/resource/pubmed/id/18317076

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-3-4
pubmed:abstractText
A 37-year-old female never smoker with metastatic large cell carcinoma of the lung had a partial response to a second line palliative therapy with the EGF-R tyrosine kinase inhibitor erlotinib after platinum based first line therapy failed. Molecular analysis of the primary and a liver metastasis did neither find any EGF-R mutation nor an EGF-R amplification. However, both the primary and the metastasis showed an increased gene expression of vascular-endothelial growth factor-A in contrast to normal tissue, which was confirmed by immunohistochemistry. To our knowledge, this is the first report about a high vascular-endothelial growth factor-A expression in the tumor of a patient responding to an EGF-R inhibitor postulating that there might be a link between both tyrosine kinase pathways.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1556-1380
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
314-6
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
pubmed:affiliation
Department of Medicine 1, University Hospital Erlangen, Ulmenweg 18, 91054 Erlangen, Germany. wolfgang.brueckl@uk-erlangen.de
pubmed:publicationType
Journal Article, Case Reports, Research Support, Non-U.S. Gov't